NCT06444165CompletedPhase 3
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
Study to Assess Lebrikizumab Pen Ease of Use in Patients With Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 29 Jul 2025
Brief summary (registry, in English)
The purpose of this study is to assess the ease of use of the lebrikizumab pen. Participants will use a practice pad to simulate administration of a dose. Participants will complete the modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ) following the simulated injection. This study involves one study visit.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 55 (actual)
- First submitted
- 31 May 2024
- Start date
- 4 Jun 2024
- Primary completion date
- 10 Jun 2024
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT06444165
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 55
- From 4 Jun 2024 to the primary completion date, 10 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Are currently enrolled or have participated in the last 3 months, in a clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
- Treatment with a live (or live attenuated) vaccine within the past 12 weeks.
Other illness
- Known hypersensitivity to any component of lebrikizumab or its excipients.
- Current or chronic infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) per participant self-report.
Other
- Cognitive or physical difficulties that could interfere with ability to understand the training, perform the injection tasks, or complete the study questionnaires as judged by the investigator.
- Is a health care practitioner who is trained in giving injections.
- Currently pregnant.
Who the study is looking for
- Self-report being diagnosed with atopic dermatitis (AD) by a physician and able to provide approximate diagnosis date.
- Autoinjector or Pen naïve \[have not used an autoinjector or pen previously; permissible to have used a pre-filled syringe (PFS) or vial and syringe\].
- Willing and able to attend an in-person interview session.
- Able to complete the protocol requirements.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Concentrics Research Coordinator of this site? Confirm its status | Indianapolis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.